Printer Friendly

ImageIQ to Act as Imaging CRO for ContraVir Pharmaceuticals Phase III Clinical Trial.

M2 PHARMA-June 9, 2015-ImageIQ to Act as Imaging CRO for ContraVir Pharmaceuticals Phase III Clinical Trial

(C)2015 M2 COMMUNICATIONS

US-based imaging software and contract research services provider ImageIQ has been chosen by US-based biopharmaceutical company ContraVir Pharmaceuticals, Inc. to provide its full complement of clinical research imaging support services and technology for ContraVir's Phase III clinical trial of FV-100, an orally available nucleoside analogue prodrug for the treatment of shingles, the company said on Tuesday.

Specifically, ContraVir will leverage ImageIQ's EDCIQ imaging-enabled electronic data capture system, customized specifically to the study's design and workflow to support the management and compliance of all imaging-related activities. ImageIQ will deploy, manage and support mobile imaging devices for field personnel who will capture images of the zoster rash for each study participant across multiple time points.

Once acquired, images and data will be automatically uploaded to the EDCIQ by a mobile application for immediate centralized QA and reporting, followed by Dermatologist image evaluation using an EDCIQ integrated image viewer and measurements tools.

Lastly, ImageIQ will develop and validate the imaging and image evaluation protocols, as well as provide image acquisition qualification, training, and imaging-related management for all study sites and field personnel participating in the study. ImageIQ is a Cleveland Clinic Innovations company.

Shingles an infection caused by the reactivation of varicella zoster virus, and shingles-associated pain, known as post-herpetic neuralgia.

ImageIQ provides image management software, image analysis capabilities, and professional services for imaging in drug and device clinical trials.

ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 9, 2015
Words:273
Previous Article:Eaton Forms Power Management Pact with the American Society for Healthcare Engineering.
Next Article:US FDA Grants Expedited Access Pathway Designation for Cohera Medical Surgical Sealant.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |